1.. INTRODUCTION {#s1}
================

The existence of Tuberculosis (TB) over the past millennia is not uncommon and outranks Human Immunodeficiency Virus (HIV) infection/acquired immunodeficiency syndrome among the 10 prominent deadliest infectious diseases worldwide. Globally, an estimated 10 million individuals suffered from TB (90% adults) in 2017 \[[@B1]\]. The increasing trend toward globalization, transnational migration, inadequate treatment of active pulmonary TB, injudicious prescriptions among physicians accompanied by uninformed drug selection as well as default among patients exposing *Mycobacterium tuberculosis* (MTB) to sublethal doses for shorter durations are potential targets for outbreaks of drug resistant (DR) TB \[[@B2],[@B3]\].

Nigeria ranks not only among the 30 countries with a significant burden of TB, TB/HIV, and DR-TB but equally among the 14 countries accounting for more than 64% of the estimated number of incident TB cases worldwide in 2017 \[[@B1]\]. Nigeria also holds a record of several reports on the occurrence of DR-TB among patients across different settings. In Nigeria, there is an estimated 4.3% and 25% of patients with Multiple Drug Resistance (MDR) among new cases and previously treated cases, respectively \[[@B4]\]. The rising drug resistance imparts a significant threat on the control of the disease by the National Tuberculosis and Leprosy Control Programme. Therefore, it is of paramount importance to predict a reliable estimate on the magnitude of DR-TB in a bid to inform policy intervention programs for better management of the disease and for the monitoring of antimicrobial resistance.

Newer technologies, especially genomic techniques, have uncovered novel avenues in curbing TB \[[@B5]\]. Genotyping of MTB Complex (MTBC) identifies and distinguishes distinct (sub) lineages that are instrumental to track and control TB \[[@B6]\], taking into consideration the existence of stable host--pathogen interaction \[[@B7]\] and phylogeographic varsity of strains \[[@B8]\]. There is a strong association of the genetic lineages with pathogenicity and resistance \[[@B9]--[@B11]\], and the genetic background of the MTBC can provide an insight in the understanding of its prevalence and transmission \[[@B12]\].

Recently transmitted and reactivation of TB disease can be differentiated using genotyping of MTBC where isolates that share the same genotype are considered clustered and are assumed to be epidemiologically linked, while isolates with unique genotype not shared by others within the population are considered to have resulted from reactivation of latent infection, presumably acquired outside the population \[[@B13]\]. Genotyping has been used in epidemiologic studies to track specific isolates of MTBC and to understand the transmission dynamics of TB. Generation of phylogenetically informative data through genotyping methods has been developed to investigate multiple MTBC clinical samples from different sources \[[@B8]\]. The lineages of MTBC can be characterized using Large Sequence Polymorphisms (LSPs) \[[@B14]\]. Regions of Difference (RD) representing the loss of genetic material in *Mycobacterium bovis* Bacillus Calmette-Guérin (BCG) compared to MTB H37Rv has been revealed using comparative genomics, and the presence or absence of these regions could be useful in MTBC differentiation. Polymerase Chain Reaction (PCR) analysis of LSPs has shown some RD loci to be restricted to one MTBC strain or subspecies, while others are differentially distributed among the other members \[[@B15]\].

A number of methods such as classification, similarity search, and expert rule-based methods have emerged to accurately map genotyped isolates using Mycobacterial Interspersed Repetitive Units (MIRU) and/or spoligotypes to the major lineages \[[@B8],[@B16],[@B17]\]. Spoligotyping is a rapid and cost-effective PCR-based reverse hybridization technique that has been used to differentiate and identify specific genotypes of MTBC. Spoligotypes have evolved through the successive loss of spacer DNA sequences that separate short, tandemly repeated DNA sequences consisting of 36 bp in the direct repeat locus of MTB. Thus, spoligotyping identifies polymorphism in the presence or absence of 43 specific DNA spacer units in the direct repeat region of the MTBC strains \[[@B18]\]. Databases for strain lineage identification that involve spoligotype signature matching have been developed \[[@B19]\].

IS*6110*, an insertion sequence found exclusively within the MTBC, has been recognized as a multicopy target with increased sensitivity for the molecular detection of the members of the complex \[[@B20]\]. The IS*6110* sequence in the genome of MTB has shown the stability required for use in molecular epidemiology. The element's presence at different locations in the genome has been extensively used for epidemiological studies and has provided a suitable method for genotyping MTBC strains \[[@B21]--[@B23]\].

Recently, several studies have been carried out in various part of the world including Africa describing the genetic diversity of MTBC \[[@B24]--[@B26]\]. Therefore, this study sought to determine the drug susceptibility as well as the genetic diversity of MTBC causing TB in the North Central zone of Nigeria.

2.. MATERIALS AND METHODS {#s2}
=========================

2.1.. Study Area, Specimen Collection, and Culture {#s2.1}
--------------------------------------------------

About 202 pure isolates were obtained from patients across the North Central zone of Nigeria (Middle Belt), which includes the following states: Benue, Kogi, Kwara, Nasarawa, Niger, Plateau, and Federal Capital Territory. The isolates were obtained following sputum collection and decontamination using *N*-acetyl [l]{.smallcaps}-cysteine--sodium hydroxide (NALC/NaOH) method from suspected TB patients with the classical symptom of prolonged cough. The culture was carried out at the Zankli Research Center, Bingham University, Nasarawa State, Nigeria, using Lowenstein--Jensen (L--J) medium incubated at 37°C for 6--8 weeks, and the positive slants were reconfirmed by acid fast bacilli microscopy following Ziehl--Neelsen staining technique. Contaminated cultures were discarded.

2.2.. Identification and Drug Susceptibility Testing {#s2.2}
----------------------------------------------------

Primary identification of MTBC was carried out using the SD BIOLINE TB Ag MPT64 RAPID kit (Standard Diagnostics, Inc., Yongin, Korea) based on the manufacturer's guide. In brief, a loopful of colonies were picked from the solid medium and suspended in 200 μL of the extraction buffer. Then 100 μL of the suspension was added to the sample well and left to flow chromatographically for 15 min. The appearance of a red band on the test window alongside with the control band was indicative of a positive result. Drug Susceptibility Testing (DST) was done by means of the proportion method on L--J medium against Isoniazid (INH; 0.2 μg/ml), Rifampicin (RIF; 40 μg/ml), Streptomycin (STR; 4 μg/ml), and Ethambutol (ETH; 2 μg/ml). The slopes were incubated at 37°C and monitored for growth at 4 and 6 weeks.

2.3.. Genotyping MTBC Isolates {#s2.3}
------------------------------

The preserved isolates from Nigeria in glycerol were shipped to the Bacteriology Laboratory of the Noguchi Memorial Institute for Medical Research (NMIMR)---Ghana, where approval from the Scientific Technical Committee and Institutional Review Board of the NMIMR was obtained for the genotyping of the isolates. The obtained DNA from heat-killed mycobacterial cell suspensions (95°C for 50 min) was subjected to molecular analyses. The primers used are shown in [Supplementary Table A](#TS1){ref-type="table"}.

### 2.3.1.. IS*6110* amplifications {#s2.3.1}

Polymerase chain reaction detection of the insertion sequence IS*6110* was carried out to confirm the MTBC. The PCR mix (50 μL) contained the following: 16.2 μL of H~2~O, 5 μL PCR buffer (10×), 10 μL Q solution, 2.5 μL MgCl~2~ (25 mM), 1 μL dNTP (10 mM), 2.5 μL primer F (10 pmol/μL), 2.5 μL primer R (10 pmol/μL), 0.3 μL Hot Start Taq DNA polymerase (5 U/μL), and 5 μL Coral dye (10×) and 5 μL of extracted mycobacterial DNA. A denaturation step was carried out at 96°C for 5 min, followed by 35 cycles of 95°C, 62°C, and 72°C for 1 min. The amplification was completed with one final extension cycle at 72°C for 10 min. Electrophoresis on 2% agarose gel was carried out on the PCR products and visualized under Ultraviolet (UV) light following ethidium bromide staining.

### 2.3.2.. Deletion analyses and spoligotyping {#s2.3.2}

The LSPs typing assay identifying RD 1, 4, 9, 12, 702, and 711 \[[@B14],[@B27]--[@B29]\] was carried out on the mycobacterial DNA. The detection of the lineage-defining LSPs was carried out by PCR using the oligonucleotide primers ([Supplementary Table A](#TS1){ref-type="table"}). In addition to a "forward" primer specific for the upstream region of each LSP, each reaction included two "reverse" primers (one internal to the deleted region and the other located immediately downstream of the LSP) \[[@B6]\].

Reactions were carried out in 25 μL volumes and included 15.4 μL of H~2~O, 2.5 μL PCR buffer (10×), 10 μL Q solution, 2.5 μL MgCl~2~ (25 mM), 0.5 μL dNTP (10 mM), 1 μL primer F (10 pmol/μL), 1 μL primer INT (10 pmol/μL), 1 μL primer DEL (10 pmol/μL), 0.1 μL Hot Start Taq DNA polymerase (5 U/μL), and 2.5 μL DNA. A denaturation step was carried out at 94°C for 2 min, followed by 35 cycles of 94°C for 10 s, 58°C for 10 s, and 72°C for 30 s. One final extension cycle at 72°C for 5 min completed the reaction. Electrophoresis on 2% agarose gel was carried out and visualized under UV light following ethidium bromide staining.

The isolates were sorted out based on the distinct phylogenetic lineages within the MTBC as previously defined \[[@B6]\]. Spoligotyping (Isogen Bioscience BV Maarssen, The Netherlands) was carried out on a membrane using the 43-spacer following manufacturer's protocol \[[@B18]\]. The positive controls used were MTB H37Rv and *Mycobacterium bovis* BCG DNAs in parallel and distilled water as the negative control.

2.4.. Data Analysis {#s2.4}
-------------------

The entire data were inputted in an Excel spreadsheet. The SpolDB4 database/MIRU-VNTRplus was used to analyze the spoligotype patterns in a binary format \[[@B30]\]. SPSS version 20.0 (IBM, Chicago, IL, USA) was used to analyze the association between the variables as age, gender, serology, drug resistance, and TB families. The *p*-value \<0.05 were considered statistically significant.

3.. RESULTS {#s3}
===========

3.1.. Demography and HIV Association {#s3.1}
------------------------------------

Of the 202 isolates included in this study, 22 (10.9%) were isolated in 2009, 15 (7.4%) in 2010, two (1%) in 2012, 11 (5.4%) in 2013, 19 (9.4%) in 2016, and the majority 133 (65.8%) in 2017. One hundred and thirty-three (65.8%) of the 202 subjects were male and 69 (34.2%) were female. The age varies from 15 to 75 years with the majority \[85/202 (42.1%)\] between 25 and 34 years. Thirty-seven (18.3%) of the 202 subjects were HIV positive, 134 (66.3%) negative, and 31 (15.3%) did not know their status. Gender was significantly associated with the HIV status (*p* = 0.009), with 19 (51.4%) of the 37 HIV-infected patients being female ([Table 1](#T1){ref-type="table"}).

###### 

HIV association with gender, rifampicin resistance, and LAM10_CAM clades in the studied subjects

                 **HIV**     **Total**   ***p*-value**         
  -------------- ----------- ----------- --------------- ----- --
  Gender         **0.009**                                     
    Male         18 (48.6)   89 (66.4)   26 (83.9)       133   
    Female       19 (51.4)   45 (33.6)   5 (16.1)        69    
  Rifampicin     **0.012**                                     
    Resistance   9 (24.3)    38 (23.4)   1 (3.2)         48    
    Sensitive    28 (75.7)   96 (71.6)   30 (96.8)       154   
  LAM10_CAM      **0.479**                                     
    Yes          21 (56.8)   85 (63.4)   22 (71)         128   
    No           16 (43.2)   49 (36.6)   9 (29)          74    
  Total          37          134         31              202   

3.2.. Drug Resistance and HIV Association {#s3.2}
-----------------------------------------

The DST result on the 202 isolates showed that 103 (51%) were pan susceptible; 51 (25.2%) were resistant to at least one drug; and 61 (30.2%), 48 (23.8%), 48 (23.8%), and 14 (6.9%) isolates were resistant to STR, INH, RIF, and ETH, respectively. MDR (RIF and INH) was observed in 29/202 (14.4%) cases and resistance to the four drugs in 2/202 (1%) isolates. HIV positivity \[37/202 (18.3%) patients\] was associated with RIF 9/37 (24.3%) resistance (*p* = 0.012) ([Table 1](#T1){ref-type="table"}).

3.3.. Distribution of Genetic Families {#s3.3}
--------------------------------------

Of the 202 isolates, 186 (92.1%) were classified as MTB, six (3%) as *Mycobacterium africanum*, two (1%) as *Mycobacterium microti*, and eight (4%) not identified. The lineages were distributed as shown in [Figure 1](#F1){ref-type="fig"}. Of the 202 isolates, 150 (74.3%) were identified as the Cameroon sublineage, followed by the UgandaI, Haarlem, and West African 1 with 18 (8.9%), 10 (5%), and 6 (3%), respectively.

![Distribution of the sublineages from the studied subjects.](JEGH-9-4-259-g001){#F1}

The spoligotype patterns recorded 58 different profiles, with 154 (76.2%) of the 202 isolates distributed 22 identified Shared International Types (SIT) according to SpolDB4 and the remaining 36 as orphans. Of the 202 isolates, 128 (63.4%) were LAM10_CAM and the most prevalent genetic family with the SIT 61 the largest cluster with 111 (55%) isolates. H3 was the second family most encountered with 11/202 (5.4%). Other genotypes included four (2%) T~2~, three (1.5%) T~1~, and two (1%) each of AFRI_2, LAM9, X3, and one (0.5%) each of AFRI_3 and CAS1_DEHLI. Forty-eight (23.8%) isolates with unknown genotype were equally recorded in this study ([Table 2](#T2){ref-type="table"}).

###### 

Distribution of genotypes, share types, and spoligotype patterns of 202 *Mycobacterium tuberculosis* complex isolates in North Central zone of Nigeria

![](JEGH-9-4-259-t001)

3.4.. Association of LAM10_CAM Family with Drug Resistance, Gender, Age, and HIV {#s3.4}
--------------------------------------------------------------------------------

The comparison between the largest family (LAM10_CAM) showed no significant association with individual drug resistance to STR (*p* = 0.287), INH (*p* = 0.841), RIF (0.841), and ETH (*p* = 0.281). However, gender with male 91/128 (71.1%) and age 25--34 years \[46/128 (35.9%)\] were significantly (*p* = 0.038 and 0.015, respectively) associated with the LAM10_CAM family ([Table 3](#T3){ref-type="table"}), but not with the HIV (*p* = 0.479) as shown in [Table 1](#T1){ref-type="table"}.

###### 

LAM10_CAM distribution of drug resistance, gender, and age of the studied subjects

             **LAM10_CAM (%)**   **Other clades (%)**   **Total**   ***p*-value**
  ---------- ------------------- ---------------------- ----------- ---------------
  STR        **0.287**                                              
    S        86 (67.2)           55 (74.3)              141         
    R        42 (32.8)           19 (25.7)              61          
  INH        **0.841**                                              
    S        97 (75.8)           57 (77)                154         
    R        31 (24.2)           17 (23)                48          
  RIF        **0.841**                                              
    S        97 (75.8)           57 (77)                154         
    R        31 (24.2)           17 (23)                48          
  ETH        **0.281**                                              
    S        121 (94.5)          67 (90.5)              188         
    R        7 (5.5)             7 (9.5)                14          
  Gender     **0.038**                                              
    Male     91 (71.1)           42 (56.8)              133         
    Female   37 (28.9)           32 (43.2)              69          
  Age        **0.015**                                              
    15--24   14 (10.9)           14 (18.9)              28          
    25--34   46 (35.9)           39 (52.7)              85          
    35--44   40 (31.3)           13 (17.6)              53          
    45--54   17 (13.3)           6 (8.1)                23          
    ≥55      11 (8.6)            2 (2.7)                13          
  Total      128                 74                     202         

STR, streptomycin; INH, isoniazid; RIF, rifampicin; ETH, ethambutol; S, sensitive; R, resistant.

4.. DISCUSSION {#s4}
==============

This study carried out in the North Central zone of Nigeria has shown a high rate of MDR-TB (14.4%) compared to previous studies carried out in the country \[[@B31],[@B32]\]. MDR-TB is a growing concern in Nigeria \[[@B31]\] and forms an important public health problem worldwide \[[@B33]\]. MDR-TB usually occurs as a consequence of injudicious adherence to TB-preventive measures or transmission of the MDR-TB strains. The burden of drug-resistant TB in Nigeria has been shown to be increasing and consequently can undermine control efforts, especially in resource-limited settings \[[@B34]\].

HIV coinfection was more prevalent in this study in females than males, contrary to a study carried out in Calabar---southeastern part of the country \[[@B35]\]. A significant association (*p* = 0.012) among HIV-positive patients with rifampicin resistance (24.3%) was recorded in this study. A similar association was observed by Adetunji et al. \[[@B36]\] in Oyo state, Nigeria, who showed a significant increase of rifampicin resistance (12%) among HIV patients with TB. Dinic et al. \[[@B37]\] also recorded a significant increase in MDR-TB including RIF (5.52%) in Lagos and Jos (two cities located in the Southwest and North Central zones of the country respectively). This is clearly above the World Health Organization predictions (0--4.3%) among HIV subjects. The authors concluded that there is a higher transmission of drug-resistant TB in HIV-infected patients in Nigeria than predicted. It has been shown that the weakening of the immune system due to HIV infection increases the burden of TB with several outcomes such as the reactivation of latent TB and equally the emergence of resistant TB strains, such as the MDR-TB \[[@B38]\]. The delay in the initiation of treatment or effective therapy, generally observed in developing countries, is a major contributor to MDR-TB increase, although TB resistance to drugs is multifactorial and clear insight can only be brought by specific investigations \[[@B39],[@B40]\].

In this study, 82.2% were aged \<45 years. TB and MDR-TB have been shown to affect the most productive age-group worldwide \[[@B41],[@B42]\]. This has been shown previously in Nigeria \[[@B43]\]. Although INH resistance was associated with male in our study (data not shown), the risk for developing susceptible TB has been shown to be linked to male sex \[[@B44]\], contrary to a study who found MDR cases more likely to affect the male and younger age \[[@B45]\]. A study observed no difference in patients' gender and MDR-TB \[[@B46]\], although conflicting results about vulnerability of female gender to MDR-TB as well as male more at risk have been reported \[[@B47]--[@B49]\].

The most prevalent spoligotype was SIT 61 (55%), which belongs to the LAM10_CAM family with 63.4% of isolates recorded in this study. A similar predominance of this family has previously been described among MTB isolates within the country \[[@B32],[@B50]--[@B52]\], as well as from the neighboring country Cameroon \[[@B53],[@B54]\] sharing a long boundary with Nigeria, and other several West African countries \[[@B55],[@B56]\]. BCG vaccination, shaping this population selection, has been hypothesized \[[@B54]\].

This study recorded a further drastic decrease of *Mycobacterium africanum*, especially SIT 331, representing only 1% as opposed to 12.35% in a study carried out merely a decade ago in the southeastern part of the country \[[@B32]\]. Although Ani et al. \[[@B52]\] equally reported around the same period the unexpected low isolation of *M. africanum* in Jos within the middle belt of the country (only one isolate), LAM10_CAM has been successfully replacing the *africanum* sublineage not only in Nigeria. This trend observed earlier across Africa shifting toward its disappearance requires a careful reexamination of the prevalence of *M. africanum* in different parts of the continent \[[@B51]\].

This study has shown an association between the age and the LAM10_CAM family (*p* = 0.015). This association has equally been demonstrated in a similar study carried out in a neighboring country \[[@B53]\], as well as within the country \[[@B32]\], where the authors observed that the age-group range 25--34 years was significantly associated with shared-type pattern SIT 61. LAM10_CAM family was not associated with HIV in this study as shown earlier in Anambra State---Nigeria, where no spoligotype pattern was associated with the infection \[[@B51]\]. Equally, no relationship was observed between the LAM10_CAM family and drug resistance, similar to previous studies \[[@B51],[@B53]\]. Since the hypothesis of the expansion of this family is as a result of vaccination selection as noted earlier, it might not yet have been subjected to drug-selective pressure. It is obvious that drug pressure is among the most important selection pressures currently taking place in MTBC, and molecular markers of drug resistance have been appropriately identified in the detection of positive selection \[[@B57]--[@B59]\]. The signature of positive selection as a result of the frequent independent occurrence of the same mutation known as convergent evolution \[[@B60]\] might not have yet occurred significantly in the LAM10_CAM family. However, considering drug misuse, defaulting, poor surveillance as well as all other factors likely to increase drug resistance such as drug administration based solely on smear microscopy still currently practiced widely in various African settings with the resultant consequences \[[@B61]\] will ineluctably result in the emergence of the Cameroon's family drug-resistant strains.

5.. CONCLUSION {#s5}
==============

Tuberculosis persists as important public health concern in Nigeria in which rifampicin resistance is of particular concern among HIV-infected patients. The abundance of the Cameroon lineage indicates an adaption, spread, and recent transmission with the risk of future evolution of drug resistance in this clade. A decreasing trend earlier noticed of the *M. africanum* lineages was observed and will require a wide evaluation. We advocate that education should be targeted toward females who happen to be the group most at risk of TB/HIV coinfection based on our findings. Improved early detection of HIV patients might help to curb the increase in MDR as well as its transmission in the studied communities. Moreover, clustered TB patients in this study probably result from recently acquired infection, and surveillance of this group is important in the control of the disease transmission.
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SUPPLEMENTARY TABLE
===================

###### 

Primers used in this study

  **Primers designation**   **5′ → 3′**
  ------------------------- -------------------------
  IS*6110*                  
  TB284                     GGACAACGCCGAATTGCG
  TB850                     TAGGCGTCGGTGACAAAGGCCAC
  AAGCGGTTGCCGCCGACCGACC    
  RD 1                      CTGGCTATATTCCTGGGCCCGG
  GAGGCGATCTGGCGGTTTGGGG    
  ATGTGCGAGCTGAGCGATG       
  RD 4                      TGTACTATGCTGACCCATGCG
  AAAGGAGCACCATCGTCCAC      
  CAAGTTGCCGTTTCGAGCC       
  RD 9                      CAATGTTTGTTGCGCTGC
  GCTACCCTCGACCAAGTGTT      
  GGGAGCCCAGCATTTACCTC      
  RD 12                     GTGTTGCGGGAATTACTCGG
  AGCAGGAGCGGTTGGATATTC     
  CAGCAGCAGGGTGTCATTGC      
  RD 702                    GCAGCAGCACGATTCCTTGC
  GATCGTCGCCGACCAGTGT       
  GGTTGGCCACTACCAGAGAC      
  RD 711                    GAACTCGCCGACTAGGTCG
  CGACGAAGTGCGTGATTTCG      

IS, insertion sequence; RD, region of difference.
